Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Coherus Oncology (CHRS) over the last 13 years, with Q3 2025 value amounting to $13.4 million.

  • Coherus Oncology's Accumulated Expenses fell 7804.48% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year decrease of 7804.48%. This contributed to the annual value of $60.3 million for FY2024, which is 4279.32% down from last year.
  • As of Q3 2025, Coherus Oncology's Accumulated Expenses stood at $13.4 million, which was down 7804.48% from $14.2 million recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Accumulated Expenses peaked at $115.7 million during Q1 2024, and registered a low of $13.4 million during Q3 2025.
  • In the last 5 years, Coherus Oncology's Accumulated Expenses had a median value of $48.1 million in 2021 and averaged $54.5 million.
  • As far as peak fluctuations go, Coherus Oncology's Accumulated Expenses skyrocketed by 26094.14% in 2024, and later crashed by 7804.48% in 2025.
  • Over the past 5 years, Coherus Oncology's Accumulated Expenses (Quarter) stood at $48.1 million in 2021, then increased by 4.09% to $50.1 million in 2022, then skyrocketed by 110.36% to $105.4 million in 2023, then tumbled by 42.79% to $60.3 million in 2024, then plummeted by 77.8% to $13.4 million in 2025.
  • Its Accumulated Expenses was $13.4 million in Q3 2025, compared to $14.2 million in Q2 2025 and $46.3 million in Q1 2025.